Evotec and The Leukemia & Lymphoma Society Enter Into a Strategic Research Collaboration
November 05 2013 - 1:37AM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) announced
today that it has entered into an integrated research collaboration
with The Leukemia & Lymphoma Society ("LLS"). Evotec will
support one of LLS's Screen-to-Lead Programs ("SLP"). In this
collaboration, Evotec partners with LLS to support selected
programmes and principal investigators with resources for
high-throughput screening and optimisation of small molecules into
drug-like compounds. Evotec delivers an industrialised,
cutting-edge, comprehensive and unbiased drug discovery
infrastructure to support innovation efficiency as part of a fully
integrated solution.
Dr Mario Polywka, Chief Operating Officer of Evotec,
commented: "We are excited to initiate this collaboration
and support The Leukemia and Lymphoma Society and their
investigators. We are confident that our experienced scientists and
innovation platform can deliver results for LLS, their
investigators and ultimately patients."
Amy Burd, Ph.D., Executive Director of Research at LLS,
added: "LLS is pleased to be working in collaboration with
Evotec to advance our Screen-to-Lead programs. We feel that Evotec
has the necessary skills and capabilities to offer significant
value to support these projects."
No financial details were disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim, MedImmune and
Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go
to www.evotec.com
ABOUT LEUKEMIA AND LYMPHOMA SOCIETY
The Leukemia & Lymphoma Society® (LLS) is the world's
largest voluntary health agency dedicated to blood cancer. The LLS
mission: Cure leukemia, lymphoma, multiple myeloma, and improve the
quality of life of patients and their families. LLS funds
lifesaving blood cancer research around the world, provides free
information and support services, and is the voice for all blood
cancer patients seeking access to quality, affordable, coordinated
care.
Founded in 1949 and headquartered in White Plains, NY, LLS has
chapters throughout the United States and Canada. To learn more,
visit www.LLS.org. Patients should
contact the Information Resource Center at (800)
955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen
Head of Corporate Communications
+49.(0)40.560 81-255
+49.(0)40.560 81-222 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024